"SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?"

"New glucose-lowering agents for type 2 diabetes are expensive compared with older drugs, so it is important for patients, those treating them, and payers that information used to guide treatment decisions is based on a clear analysis of the benefits and risks of each drug."

Click here to read the full article

Source- http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)00084-X/abstract

#SGLT2 #cardiology #Type2diabetes #news

Must Read